Hasumi
International Research
Foundation
The headquarters of the Hasumi Foundation was
physically established on May 1, 1999, in the
Thomas Jefferson University in Philadelphia, one
of the most advanced and renowned academic research
institutes for immunotherapy.
Although the University and the Hasumi Foundation
are independent of each other, the Hasumi Foundation
will have a high level of academic support from
the University to efficiently and adequately corroborate
research activity internationally. Currently,
the Hasumi Foundation is supporting cancer research
in the United States, Japan, China and Brazil. |
Dr.
Kenichiro HASUMI
Chairman & CEO
Dr. Kenichiro Hasumi is a physician, specialized
in cancer immunotherapy and terminal care. He
is also a researcher and visionary, focused on
the development of cancer vaccines and improved
clinical treatments to achieve better patient
outcomes with a higher quality of life.
Dr. Hasumi is also responsible for immunotherapy
by use of the Hasumi vaccine. The Hasumi vaccine
has been used by over 100,000 cancer patients
during the past fifty years in more than twenty
countries, without the occurrence of any severe
side effect. Dr. Hasumi intends to devote all
of his abilities and his experience to direct
and manage the Hasumi Foundation for the benefit
of human kind.
Dr. Hasumi also is chairman of Shukokai Clinic,
Hijirigaoka Hospital, Hijiri-no-Sato Elderly Health
Care Facility, and The Electro-Chemical and Cancer
Institute; all these institutions are located
in Tokyo, Japan. He was also the primary organizer
and founder for the World Immuno-Society for Health
(WISH), a nonprofit organization helping physicians,
patients and their families become more aware
and understanding of cancer treatment and care
through networking.
|